Fairy 1
- Scientists are in a race to come up with ways to eliminate the often deadly bacteria from the food system. - Made-in-Canada solution is about to hit the mass market in the form of a vaccine that would inoculate cows for the most common strain. - Peer-reviewed studies conducted with the vaccine have proven it can effectively reduce the amount of O157:H7 E. coli in a cow's digestive tract by 99 per cent - Canada has scant production capacity for veterinary vaccines and imports most of its treatments from the United States - Widespread dissemination of the vaccine has been hampered by lack of facilities to mass-produce it. - $25-million in loans from the provincial and federal governments, Bioniche recently built a state-of-the-art facility that, at capacity, will churn out 500 million doses annually of the vaccine - By year's end, it will be producing 100 million doses - enough to vaccinate all of Canada's 12.5 million cattle and nearly all of the 92.6 million that U.S. officials say are in the United States. - US - Bioniche Life Sciences, Inc., an Ontario-based biopharmaceutical firm, is in a tense impasse with APHIS over its rejection of a vaccine that the company says can reduce the shedding of E. coli O157:H7 in cattle - https://www.thecattlesite.com/news/20769/bioniche-in-standoff-with-aphis-over-ie-coli-i-vaccine/#sthash.BfQhlBEj.dpuf - USDA told Bioniche that the vaccine is eligible for a conditional license, as long as the company develops a plan that would collect enough data to move to a full license. If it gets a conditional licence, Bioniche would have full access to the U.S. market, - Company needs to persuade farmers - or governments - to buy - Bioniche, the Canadian company that manufactured Econiche.....sold its animal health arm to Ventoquinol, a French company who have now ceased production of Econiche. - E-coli vaccine produced by Bioniche and used by a number of NFAN members is no longer available